• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种使用已发表的 P 值从 Kaplan-Meier 生存图中提取汇总统计量的非线性优化方法。

A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.

机构信息

Faculty of Medicine, University of Southampton, Southampton, UK.

Present Address: Department of Pathology and Data Analytics, University of Leeds, Leeds, UK.

出版信息

BMC Med Res Methodol. 2020 Oct 30;20(1):269. doi: 10.1186/s12874-020-01092-x.

DOI:10.1186/s12874-020-01092-x
PMID:33126853
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7596943/
Abstract

BACKGROUND

Meta-analyses of studies evaluating survival (time-to-event) outcomes are a powerful technique to assess the strength of evidence for a given disease or treatment. However, these studies rely on the adequate reporting of summary statistics in the source articles to facilitate further analysis. Unfortunately, many studies, especially within the field of prognostic research do not report such statistics, making secondary analyses challenging. Consequently, methods have been developed to infer missing statistics from the commonly published Kaplan-Meier (KM) plots but are liable to error especially when the published number at risk is not included.

METHODS

We therefore developed a method using non-linear optimisation (nlopt) that only requires the KM plot and the commonly published P value to better estimate the underlying censoring pattern. We use this information to then calculate the natural logarithm of the hazard ratio (ln (HR)) and its variance (var) ln (HR), statistics important for meta-analyses.

RESULTS

We compared this method to the Parmar method which also does not require the number at risk to be published. In a validation set consisting of 13 KM studies, a statistically significant improvement in calculating ln (HR) when using an exact P value was obtained (mean absolute error 0.014 vs 0.077, P = 0.003). Thus, when the true HR has a value of 1.5, inference of the HR using the proposed method would set limits between 1.49/1.52, an improvement of the 1.39/1.62 limits obtained using the Parmar method. We also used Monte Carlo simulations to establish recommendations for the number and positioning of points required for the method.

CONCLUSION

The proposed non-linear optimisation method is an improvement on the existing method when only a KM plot and P value are included and as such will enhance the accuracy of meta-analyses performed for studies analysing time-to-event outcomes. The nlopt source code is available, as is a simple-to-use web implementation of the method.

摘要

背景

评估生存(时间事件)结局的荟萃分析是评估特定疾病或治疗方法证据强度的有力技术。然而,这些研究依赖于源文章中充分报告汇总统计数据,以方便进一步分析。不幸的是,许多研究,尤其是预后研究领域的研究,没有报告这些统计数据,使得二次分析具有挑战性。因此,已经开发了一些方法从常见的发表的 Kaplan-Meier(KM)图中推断缺失的统计数据,但这些方法容易出错,特别是当发表的风险人数不包括在内时。

方法

因此,我们开发了一种使用非线性优化(nlopt)的方法,该方法仅需要 KM 图和常见的发表的 P 值,以更好地估计潜在的删失模式。我们利用这些信息来计算对数风险比(ln(HR))及其方差(var)ln(HR),这些统计数据对于荟萃分析很重要。

结果

我们将这种方法与 Parmar 方法进行了比较,Parmar 方法也不需要发表风险人数。在一个由 13 项 KM 研究组成的验证集中,当使用精确的 P 值时,计算 ln(HR)的统计学显著改善(平均绝对误差 0.014 与 0.077,P = 0.003)。因此,当真实的 HR 值为 1.5 时,使用建议方法推断 HR 的值将在 1.49/1.52 之间设置限制,这比使用 Parmar 方法获得的 1.39/1.62 限制有所改善。我们还使用蒙特卡罗模拟来确定方法所需的点数和位置的建议。

结论

当仅包含 KM 图和 P 值时,所提出的非线性优化方法是现有方法的改进,因此将提高对分析时间事件结局的研究进行荟萃分析的准确性。nlopt 源代码和方法的简单易用的网络实现都可用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/d621de3909df/12874_2020_1092_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/e5be7f0c8143/12874_2020_1092_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/a32db1adea92/12874_2020_1092_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/d00909a530c5/12874_2020_1092_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/aeef1ffa6fec/12874_2020_1092_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/6207a0a72cf9/12874_2020_1092_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/d621de3909df/12874_2020_1092_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/e5be7f0c8143/12874_2020_1092_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/a32db1adea92/12874_2020_1092_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/d00909a530c5/12874_2020_1092_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/aeef1ffa6fec/12874_2020_1092_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/6207a0a72cf9/12874_2020_1092_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e8de/7596943/d621de3909df/12874_2020_1092_Fig6_HTML.jpg

相似文献

1
A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.一种使用已发表的 P 值从 Kaplan-Meier 生存图中提取汇总统计量的非线性优化方法。
BMC Med Res Methodol. 2020 Oct 30;20(1):269. doi: 10.1186/s12874-020-01092-x.
2
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析:从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.
3
Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.从发表的 Kaplan-Meier 生存曲线估计风险比:方法验证研究。
Res Synth Methods. 2019 Sep;10(3):465-475. doi: 10.1002/jrsm.1362. Epub 2019 Jun 24.
4
Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.个体患者数据荟萃分析中估计受限平均生存时间差异的方法的偏倚和精度。
BMC Med Res Methodol. 2016 Mar 29;16:37. doi: 10.1186/s12874-016-0137-z.
5
A note on estimating treatment effect for time-to-event data in a literature-based meta-analysis.基于文献的荟萃分析中事件发生时间数据治疗效果估计的说明。
Methods Inf Med. 2009;48(2):104-12. doi: 10.3414/ME0535. Epub 2009 Feb 18.
6
Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews.对荟萃分析中生存时间结局进行二元分析的影响:来自 Cochrane 系统评价数据库的实证证据。
BMC Med Res Methodol. 2022 Mar 20;22(1):73. doi: 10.1186/s12874-022-01541-9.
7
KMSubtraction: reconstruction of unreported subgroup survival data utilizing published Kaplan-Meier survival curves.KMSubtraction:利用已发表的 Kaplan-Meier 生存曲线重建未报告亚组生存数据。
BMC Med Res Methodol. 2022 Apr 3;22(1):93. doi: 10.1186/s12874-022-01567-z.
8
Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.EZH2 在非小细胞肺癌中的预后价值:一项荟萃分析和生物信息学分析。
Biomed Res Int. 2020 Nov 9;2020:2380124. doi: 10.1155/2020/2380124. eCollection 2020.
9
Visualizing length of survival in time-to-event studies: a complement to Kaplan-Meier plots.在事件发生时间研究中可视化生存时间:对Kaplan-Meier曲线的一种补充。
J Natl Cancer Inst. 2008 Jan 16;100(2):92-7. doi: 10.1093/jnci/djm265. Epub 2008 Jan 8.
10
Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.生存因果效应的 Kaplan-Meier 曲线与事件时间结局。
Clin Trials. 2013 Aug;10(4):515-21. doi: 10.1177/1740774513483601. Epub 2013 Apr 22.

引用本文的文献

1
Clinical and prognostic characteristics of bilateral Wilms tumor: a multi-center institutional retrospective cohort study experience from China.双侧肾母细胞瘤的临床及预后特征:一项来自中国的多中心机构回顾性队列研究经验
World J Pediatr. 2025 Apr 17. doi: 10.1007/s12519-025-00895-6.
2
Prognostic value of cyclin B1 and cyclin B2 expression in breast cancer: A systematic review and updated meta-analysis.Cyclin B1 和 cyclin B2 表达在乳腺癌中的预后价值:系统评价和更新的荟萃分析。
Medicine (Baltimore). 2024 Jan 19;103(3):e37016. doi: 10.1097/MD.0000000000037016.
3
Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis.

本文引用的文献

1
Estimating hazard ratios from published Kaplan-Meier survival curves: A methods validation study.从发表的 Kaplan-Meier 生存曲线估计风险比:方法验证研究。
Res Synth Methods. 2019 Sep;10(3):465-475. doi: 10.1002/jrsm.1362. Epub 2019 Jun 24.
2
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.硼替佐米联合标准化疗免疫治疗弥漫性大 B 细胞淋巴瘤(REMoDL-B)的基因表达谱分析:一项开放标签、随机、3 期临床试验。
Lancet Oncol. 2019 May;20(5):649-662. doi: 10.1016/S1470-2045(18)30935-5. Epub 2019 Apr 1.
3
Combined test versus logrank/Cox test in 50 randomised trials.
早期和极早期肝细胞癌的消融和非手术治疗:系统评价和网络荟萃分析。
Health Technol Assess. 2023 Dec;27(29):1-172. doi: 10.3310/GK5221.
4
Prognostic Significance of Programmed Cell Death Ligand 1 Expression in High-Grade Serous Ovarian Carcinoma: A Systematic Review and Meta-Analysis.程序性细胞死亡配体1在高级别浆液性卵巢癌中的表达的预后意义:一项系统评价和荟萃分析
Diagnostics (Basel). 2023 Oct 19;13(20):3258. doi: 10.3390/diagnostics13203258.
5
A Method for Reconstructing Individual Patient Data From Kaplan-Meier Survival Curves That Incorporate Marked Censoring Times.一种从包含显著删失时间的Kaplan-Meier生存曲线重建个体患者数据的方法。
MDM Policy Pract. 2022 Jan 31;7(1):23814683221077643. doi: 10.1177/23814683221077643. eCollection 2022 Jan-Jun.
6
Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis.描绘非小细胞肺癌中癌症相关成纤维细胞异质性:系统评价和荟萃分析。
Sci Rep. 2021 Feb 12;11(1):3727. doi: 10.1038/s41598-021-81796-2.
50项随机试验中联合检验与对数秩检验/考克斯检验的比较
Trials. 2019 Mar 18;20(1):172. doi: 10.1186/s13063-019-3251-5.
4
Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.多指标免疫组化评估可切除非小细胞肺癌中巨噬细胞表型的预后价值。
Neoplasia. 2019 Mar;21(3):282-293. doi: 10.1016/j.neo.2019.01.005. Epub 2019 Feb 10.
5
A guide to systematic review and meta-analysis of prognostic factor studies.预后因素研究的系统评价与Meta分析指南
BMJ. 2019 Jan 30;364:k4597. doi: 10.1136/bmj.k4597.
6
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.贝伐珠单抗辅助治疗高复发风险黑色素瘤患者:AVAST-M 试验的生存分析。
Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229.
7
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): An Abridged Explanation and Elaboration.报告肿瘤标志物预后研究推荐(REMARK):摘要解释和详细说明。
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811. doi: 10.1093/jnci/djy088.
8
Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.组织分析揭示了FAP-1阳性成纤维细胞在非小细胞肺癌中的潜在免疫佐剂功能。
PLoS One. 2018 Feb 7;13(2):e0192157. doi: 10.1371/journal.pone.0192157. eCollection 2018.
9
Reconstructing time-to-event data from published Kaplan-Meier curves.从已发表的卡普兰-迈耶曲线重建事件发生时间数据。
Stata J. 2017 Oct;17(4):786-802.
10
( promoter hypermethylation and response to irinotecan in metastatic colorectal cancer.(启动子高甲基化与转移性结直肠癌对伊立替康的反应)
Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 8.